Reading Through the Nonsense: Gentamicin and ELX-02 As Rescuing Therapies for Epidermolysis Bullosa
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Leubitz A, Frydman-Marom A, Sharpe N, van Duzer J, Campbell K, Vanhoutte F
. Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2019; 8(8):984-994.
DOI: 10.1002/cpdd.647.
View
2.
Mosallaei D, Hao M, Antaya R, Levian B, Kwong A, Cogan J
. Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants. JAMA Dermatol. 2022; 158(4):366-374.
PMC: 8892363.
DOI: 10.1001/jamadermatol.2021.5992.
View
3.
Hammersen J, Has C, Naumann-Bartsch N, Stachel D, Kiritsi D, Soder S
. Genotype, Clinical Course, and Therapeutic Decision Making in 76 Infants with Severe Generalized Junctional Epidermolysis Bullosa. J Invest Dermatol. 2016; 136(11):2150-2157.
DOI: 10.1016/j.jid.2016.06.609.
View
4.
Kwong A, Cogan J, Hou Y, Antaya R, Hao M, Kim G
. Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations. Mol Ther. 2020; 28(5):1327-1338.
PMC: 7210719.
DOI: 10.1016/j.ymthe.2020.03.006.
View
5.
Haverty T, Wyatt D, Porter K, Leubitz A, Banks K, Goodyer P
. Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX-02 in Patients With Nephropathic Cystinosis. J Clin Pharmacol. 2020; 61(7):923-931.
PMC: 8248099.
DOI: 10.1002/jcph.1807.
View